company background image
BLU

BELLUS Health TSX:BLU Stock Report

Last Price

CA$15.15

Market Cap

CA$1.9b

7D

17.7%

1Y

288.5%

Updated

10 Aug, 2022

Data

Company Financials +
BLU fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BLU Stock Overview

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications.

BELLUS Health Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BELLUS Health
Historical stock prices
Current Share PriceCA$15.15
52 Week HighCA$16.24
52 Week LowCA$3.69
Beta-0.56
1 Month Change20.53%
3 Month Change48.24%
1 Year Change288.46%
3 Year Change64.39%
5 Year Change1,022.22%
Change since IPO-98.41%

Recent News & Updates

May 05
We're Hopeful That BELLUS Health (TSE:BLU) Will Use Its Cash Wisely

We're Hopeful That BELLUS Health (TSE:BLU) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, BELLUS Health ( TSE:BLU...

Shareholder Returns

BLUCA BiotechsCA Market
7D17.7%8.2%1.9%
1Y288.5%8.8%-1.1%

Return vs Industry: BLU exceeded the Canadian Biotechs industry which returned 7.9% over the past year.

Return vs Market: BLU exceeded the Canadian Market which returned -2% over the past year.

Price Volatility

Is BLU's price volatile compared to industry and market?
BLU volatility
BLU Average Weekly Movement11.3%
Biotechs Industry Average Movement12.9%
Market Average Movement10.8%
10% most volatile stocks in CA Market19.4%
10% least volatile stocks in CA Market4.3%

Stable Share Price: BLU is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: BLU's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199340Roberto Bellinihttps://www.bellushealth.com

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.

BELLUS Health Fundamentals Summary

How do BELLUS Health's earnings and revenue compare to its market cap?
BLU fundamental statistics
Market CapUS$1.49b
Earnings (TTM)-US$69.82m
Revenue (TTM)US$16.00k

Over9,999x

P/S Ratio

-21.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BLU income statement (TTM)
RevenueUS$16.00k
Cost of RevenueUS$0
Gross ProfitUS$16.00k
Other ExpensesUS$69.84m
Earnings-US$69.82m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.56
Gross Margin100.00%
Net Profit Margin-436,406.25%
Debt/Equity Ratio0%

How did BLU perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BLU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BLU?

Other financial metrics that can be useful for relative valuation.

BLU key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue79071x
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does BLU's PB Ratio compare to its peers?

BLU PB Ratio vs Peers
The above table shows the PB ratio for BLU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average21.7x
SVA Sernova
13.9x-17.5%CA$329.8m
EDT Spectral Medical
66.1x79.6%CA$142.1m
BCT BriaCell Therapeutics
2.3x-25.5%CA$131.7m
MDNA Medicenna Therapeutics
4.5x44.0%CA$93.1m
BLU BELLUS Health
5.3x53.3%CA$1.9b

Price-To-Book vs Peers: BLU is good value based on its Price-To-Book Ratio (5.3x) compared to the peer average (21.7x).


Price to Earnings Ratio vs Industry

How does BLU's PE Ratio compare vs other companies in the CA Biotechs Industry?

Price-To-Book vs Industry: BLU is expensive based on its Price-To-Book Ratio (5.3x) compared to the Canadian Biotechs industry average (3x)


Price to Book Ratio vs Fair Ratio

What is BLU's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BLU PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BLU's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of BLU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BLU (CA$15.15) is trading above our estimate of fair value (CA$5.39)

Significantly Below Fair Value: BLU is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is BELLUS Health forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


53.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BLU is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BLU is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BLU is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BLU's revenue (82.6% per year) is forecast to grow faster than the Canadian market (6.3% per year).

High Growth Revenue: BLU's revenue (82.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BLU's Return on Equity is forecast to be low in 3 years time (16.7%).


Discover growth companies

Past Performance

How has BELLUS Health performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-58.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BLU is currently unprofitable.

Growing Profit Margin: BLU is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BLU is unprofitable, and losses have increased over the past 5 years at a rate of 58.5% per year.

Accelerating Growth: Unable to compare BLU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BLU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (47.6%).


Return on Equity

High ROE: BLU has a negative Return on Equity (-24.96%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is BELLUS Health's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BLU's short term assets ($245.0M) exceed its short term liabilities ($16.0M).

Long Term Liabilities: BLU's short term assets ($245.0M) exceed its long term liabilities ($554.0K).


Debt to Equity History and Analysis

Debt Level: BLU is debt free.

Reducing Debt: BLU has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BLU has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: BLU has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 50.1% each year.


Discover healthy companies

Dividend

What is BELLUS Health current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BLU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BLU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BLU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BLU's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BLU has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Roberto Bellini (42 yo)

12.58yrs

Tenure

US$1,783,510

Compensation

Mr. Roberto Francesco Bellini has been the Chief Executive Officer and President of BELLUS Health Inc, since January 1, 2010. Mr. Bellini served as an Executive Vice President of Picchio Pharma Inc. until...


CEO Compensation Analysis

Compensation vs Market: Roberto's total compensation ($USD1.78M) is about average for companies of similar size in the Canadian market ($USD2.30M).

Compensation vs Earnings: Roberto's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: BLU's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

Experienced Board: BLU's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 60.6%.


Top Shareholders

Company Information

BELLUS Health Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: BELLUS Health Inc.
  • Ticker: BLU
  • Exchange: TSX
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$1.906b
  • Shares outstanding: 125.79m
  • Website: https://www.bellushealth.com

Number of Employees


Location

  • BELLUS Health Inc.
  • 275 Armand-Frappier Boulevard
  • Laval
  • Quebec
  • H7V 4A7
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/10 00:00
End of Day Share Price2022/08/10 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.